San Jose, CA (PRWEB) November 05, 2013
Colby Pharmaceutical Company (CPC) announces ground-breaking results demonstrating that two inoculations of Colby’s JVRS-100 adjuvant, in combination with Fluzone influenza vaccine, enhance the efficacy of this vaccine in elderly rhesus macaque monkeys and protect these immunized primates against the live influenza virus.
This research was performed in collaboration with investigators at the University of California, the Davis Center for Comparative Medicine, and the California National Primate Research Center. A resulting manuscript, “The effectiveness of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/DNA adjuvant,” has now been published in the Advanced Access edition of the Journal of Infectious Diseases. The Journal of Infectious Disease has also included an accompanying editorial entitled, “Towards improved influenza vaccines.”
The editorial concludes that, “Overall, there is a great need to develop better influenza vaccines for the elderly and other vulnerable groups. The work described by Carroll et al provides another promising approach moving towards human efficacy trials.”
The studies were coordinated by Colby’s VP of Research, Jeff Fairman, Ph.D., in collaboration with Professor Chris Miller, D.V.M., Ph.D., University of California, Davis. Timothy Carroll, PhD, is a postdoctoral scholar at the Center for Comparative Medicine, University of California, Davis, working in Dr. Chris Miller’s lab on eliciting broadly protective antibodies in the rhesus macaque model for human influenza. He also recently presented additional studies at the California National Primate Research Center, entitled, “A whole inactivated H3N2 Influenza A virus vaccine adjuvanted with a cationic lipid/DNA complex (CLDC) protects rhesus macaques from heterosubtypic H1N1 Influenza A virus challenge.”<
Copyright©2012 Vocus, Inc.
All rights reserved